A Phase 1 Study of KIN-2787 in People With Advanced Cancers


Full Title

A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants with BRAF and/or NRAS Mutation-positive Solid Tumors


Researchers want to find the best dose of KIN-2787 to give with or without binimetinib to treat advanced cancer. People in this study have non-small cell lung cancer with a change (mutation or variant) in the BRAF gene. The study also includes people with melanoma containing a mutation in the NRAS gene.

KIN-2787 targets BRAF mutations, and this targeting action may kill cancer cells. Binimetinib blocks signals involved in cancer growth. Combining these two drugs may more fully stop growth signals in cancer cells. Both medications are taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have non-small cell lung cancer that cannot be surgically removed or has spread to other organs, with an appropriate BRAF mutation, OR
  • Have metastatic melanoma with an appropriate change in the NRAS gene.
  • Have completed previous treatment at least 4 weeks before getting the study treatment.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information and to see if you can join this study, please contact Dr. Michael Offin’s office at 646-608-3763.




Phase I (phase 1)

Disease Status

Newly Diagnosed & Relapsed/Refractory


ClinicalTrials.gov ID